Provided by Tiger Trade Technology Pte. Ltd.

Capricor Therapeutics

10.44
+0.53005.35%
Volume:2.62M
Turnover:27.48M
Market Cap:606.97M
PE:-4.23
High:11.00
Open:10.77
Low:10.21
Close:9.91
52wk High:40.37
52wk Low:2.96
Shares:58.14M
Float Shares:45.54M
Volume Ratio:1.09
T/O Rate:5.75%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.4659
EPS(LYR):-2.2601
ROE:-73.70%
ROA:-33.63%
PB:2.47
PE(LYR):-4.62

Loading ...

Capricor CFO Anthony Bergmann Disposes of USD 732,158 in Common Shares

Reuters
·
Jun 30

Capricor Therapeutics Gets FDA Advisory Panel Meeting for Duchenne Therapy

MT Newswires Live
·
Jun 29

Capricor Therapeutics (CAPR) Is Down 6.8% After Positive Five-Year HOPE-2 DMD Data And FDA Update

Simply Wall St.
·
Jun 28

What's Going On With Capricor Therapeutics Stock On Friday?

Benzinga
·
Jun 27

Capricor Tumbles as FDA Panel Meet for Duchenne Cell Therapy Adds Risk Worries

Reuters
·
Jun 26

Capricor Therapeutics to Face FDA Advisory Panel Review of Deramiocel BLA in Duchenne Muscular Dystrophy

Reuters
·
Jun 26

Capricor announces FDA advisory committee meeting to review Deramiocel BLA

TIPRANKS
·
Jun 26

Capricor Therapeutics Says Deramiocel BLA PDUFA Target Action Date Set for August 22

Reuters
·
Jun 26

Capricor Therapeutics Announces FDA Advisory Committee Meeting to Review Bla for Deramiocel for the Treatment of Duchenne Muscular Dystrophy

THOMSON REUTERS
·
Jun 26

Capricor Therapeutics - Deramiocel Bla Pdufa Target Action Date Set for August 22, 2026

THOMSON REUTERS
·
Jun 26

Capricor presents five-year data from HOPE-2 open-label extension study

TIPRANKS
·
Jun 26

Capricor Says Deramiocel Meets Primary Endpoint in Hope-3 Phase 3 Duchenne Muscular Dystrophy Trial

Reuters
·
Jun 26

Capricor Therapeutics EVP, General Counsel Karen Krasney Sells 900 Shares for $27,000

Reuters
·
Jun 25

Analysts Offer Insights on Healthcare Companies: Odyssey Therapeutics, Inc. (ODTX), Capricor Therapeutics (CAPR) and Medtronic (MDT)

TIPRANKS
·
Jun 18

Capricor Therapeutics shareholders reject officer exculpation charter amendment at annual meeting

Reuters
·
Jun 09

Capricor Therapeutics to present at Goldman Sachs Global Healthcare Conference

Reuters
·
Jun 08

Why Capricor Therapeutics (CAPR) Is Down 10.8% After FDA Clears Key Deramiocel Inspection Step

Simply Wall St.
·
Jun 07

Capricor publishes investor presentation on deramiocel Duchenne muscular dystrophy program

Reuters
·
May 29

Capricor names Michael Maurer chief commercial officer

Reuters
·
May 29

Capricor Therapeutics files Form 3 for Chief Commercial Officer Michael T. Maurer

Reuters
·
May 29